Explore the latest GLP-1 weight loss drugs, ongoing clinical trials, and emerging oral treatments for obesity. Discover how Eli Lilly, Novo Nordisk, Pfizer, and Roche are advancing their drug pipelines and competing in the obesity treatment market.
Obesity is a rising concern among individuals globally, with over 1.1 billion people living with obesity. The obesity risk has increased due to improvements in food security, socioeconomic development, and behavioral norms. These aspects lead to unhealthy weight gain and make prevention and treatment more difficult. This encourages researchers to develop novel anti-obesity therapeutics that target glucagon-like peptide 1 (GLP-1) receptors.
Significance of GLP-1 Agonists
GLP-1 agonists are a class of medications that manage blood glucose levels in patients with Type 2 diabetes and lead to weight loss in obesity. GLP-1 agonists trigger insulin release from the pancreas, block glucagon secretion, slow stomach emptying, and increase satiety. GLP-1 agonist medications work by mimicking the GLP-1 hormone.
Among obesity patients, GLP-1 medications work by triggering insulin release, reducing glucose production in the liver, and making the patients feel full. Researchers have identified potential benefits of GLP-1 agonists, such as lowering blood pressure, improving lipid disorders, improving fatty liver disease, and reducing the risk of heart or kidney diseases. The U.S. Food and Drug Administration (FDA) has approved two GLP-1 medications for weight loss, including Ozempic and Wegovy (semaglutide).
Need for Oral GLP-1 Agonists
Both FDA-approved medications are available in injectable forms. Injectable medications carry challenges related to drug delivery, such as the need for a trained professional to administer the drug and injection site reactions. This reduces patient compliance and leads to a high cost of treatment. Thus, researchers focus on developing a more convenient treatment option in the pill format. Oral GLP-1 drugs provide a needle-free alternative to weekly or daily injections for managing blood sugar and chronic weight loss.
When the GLP-1 agonist is administered orally, the active molecule binds to GLP-1 receptors in the brain, gut, and pancreas. It primarily works through three key mechanisms, including signaling the brain’s full appetite centers; slowing gastric emptying so food stays in the stomach longer and satiety lasts; and stimulating insulin release after meals, which helps stabilize blood sugar. GLP-1 pills work best alongside dietary changes and regular physical activity.
| Features | Oral Tablet | Injectable Medication |
| Route | Swallowed daily, fasting conditions | Subcutaneous injection, weekly or daily |
| Bioavailability | Lower | Higher |
| Dosing frequency | Once daily | Once weekly |
| Needle-free | Yes | No |
| Adherence challenge | Strict empty-stomach timing | Comfort with self-injection |
Latest Clinical Trials Related to GLP-1 Medications
Clinical trials are essential to test the safety and efficacy of new GLP-1 candidates among patients with type 2 diabetes and obesity. As of 17th November 2026, about 38 active, not recruiting clinical trials were registered on the clinicaltrials.gov website related to GLP-1 drugs. Of these, 3 were in Phase I, 7 were in Phase II, 6 were in Phase III, and 9 were in Phase IV trials.
| Drugs | Trial Stage | Developer/Manufacturer |
| Aleniglipron (GSBR-1290) | Phase III | Structure Therapeutics |
| APHD-012 | Phase II | Aphaia Pharma |
| ARD-101 | Phase II | Aardvark Therapeutics |
| Amycretin | Phase III | Novo Nordisk |
| Monlunabant | Phase II | Novo Nordisk |
| Retatrutide | Phase III | Eli Lilly |
| CagriSema | Phase III | Novo Nordisk |
| Ecnoglutide | Phase III | Sciwind Biosciences |
| Mazdutide | Phase III | Innovent Biologics and Eli Lilly |
| Survodutide | Phase II | Boehringer Ingelheim |
| VK2735 | Phase II | Viking Therapeutics |
| MariTide | Phase III | Amgen |
| PF-08653944 | Phase III | Pfizer |
| Eloralintide | Phase III | Eli Lilly |
The table above lists various GLP-1 weight loss drugs that are in Phase II/III of clinical trials.
Pharma Competition for the GLP-1 Weight Loss Drugs
Numerous pharmaceutical companies compete with each other in terms of oral vs. injectable drugs, body composition therapies, and other non-incretin mechanisms.
Eli Lilly
Eli Lilly has the broadest portfolio of GLP-1 drugs in the pharmaceutical industry. Its commercial drugs include tirzapetide and newly approved oral GLP-1, Foundayo. Its late-stage pipeline includes retatrutide, eloralintide, and bimagrumab. The company distinguishes itself by developing therapies across obesity and cardiometabolic conditions.
Novo Nordisk
Novo Nordisk focuses on expanding its established incretin franchise into the amylin and combination era. CagriSema, Cagrilintide, and zenagamtide are its GLP-1 drugs under investigation.
Pfizer
Pfizer has rebuilt its obesity strategy through business development, particularly after the acquisition of Metsera. The company aims to sponsor 20 obesity trials during 2026, including 10 ongoing Phase III trials for PF-08653944.
Roche
Roche has built one of the fastest-expanding obesity portfolios through acquisition and collaboration. Its pipeline comprises of Enicepatide, petrelintide, and CT-996, which are under clinical development.
Conclusion
GLP-1 weight loss drugs are transforming the obesity treatment landscape by offering effective, evidence-based approaches to weight management and metabolic health. While injectable GLP-1 agonists have demonstrated significant clinical benefits, the growing need for convenient oral formulations is encouraging pharmaceutical companies to develop more accessible and patient-friendly treatment options. Ongoing clinical trials are further expanding the therapeutic potential of GLP-1 medications, exploring newer formulations, improved efficacy, and innovative approaches.
Meanwhile, increasing competition among Eli Lilly, Novo Nordisk, Pfizer, and Roche is accelerating innovation in the GLP-1 market. As these companies invest in next-generation therapies and compete to strengthen their market positions, the industry is moving toward more effective, convenient, and potentially accessible weight loss treatments. The future of GLP-1 medications will depend on clinical outcomes, affordability, regulatory approvals, and their ability to address the growing burden of obesity.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.
Request Consultation